KR930702371A - 뉴클레오시드 유도체 - Google Patents

뉴클레오시드 유도체

Info

Publication number
KR930702371A
KR930702371A KR1019930701006A KR930701006A KR930702371A KR 930702371 A KR930702371 A KR 930702371A KR 1019930701006 A KR1019930701006 A KR 1019930701006A KR 930701006 A KR930701006 A KR 930701006A KR 930702371 A KR930702371 A KR 930702371A
Authority
KR
South Korea
Prior art keywords
compound
infection
virus
treatment
formula
Prior art date
Application number
KR1019930701006A
Other languages
English (en)
Inventor
뵈른 올로프 클라손
벤그트 베르틸 사뮤엘손
잉게마르 스벤-안데르스 크바른스트룀
라르스 괴란 스반손
스테판 칼 토레 스벤손
Original Assignee
닐스 군나르 요한슨
메디비르 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 닐스 군나르 요한슨, 메디비르 에이비 filed Critical 닐스 군나르 요한슨
Publication of KR930702371A publication Critical patent/KR930702371A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

본 발명은 α-또는 β-아노머 또는 그의 혼합물 형태의 하기 일반식(1A) 및 (1B)의 신규 항바이러스성 화합물 및 그의 제약상 허용되는 염 및 그의 신규 제조방법에 관한 것이다.
상기 식중, X 및 R1-R4는 특허 청구의 범위 제1항에서 정의한 바와 같다.
이들 화합물은 HIV 및 간현B 바이러스와 같이 복제에 역제에 역전사효소를 요하는 바이러스에 의한 감염증의 치료에 사용할 수 있다.

Description

뉴클레오시드 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (39)

  1. α-및 β-아노머(anomer)의 혼합물 또는 α-및 β-아노머 형태의 하기 일반식의 화합물 또는 그의 제약상 허용되는 염.
  3. 상기 식 중, X는 O,S,SO,SO2,CH2이고, R1은 OH, O-PO(OH)2, O-PO(OH)-O-PO-(OH)2, O-PO-(OH)-O-PO(OH)-O-PO(OH)2, 또는 (CH2)nOCH2PO(OH|2)(여기서, n은 0내지 2임)이며, R2는 H이고, R3은 CH3, CH2OH, CH2OnCH|3, CH2SH, CH2F 또는 CH2N3이거나, 또는 R3은 H이고, R2는 CH3, CH2OH, CH2OCH3, CH2SH, CH2F 또는 CH2N3이며 R4는또는이고, 여기서 Y는 OH, NH2이고 R5는 CH=CH2, C≡CH, CH=CH-CH3, C≡C-CH3, 티엔-2-일, 티엔-3-일, H, CH3, C2H|5, CH2CH2CH3또는 CH(CH3)2이며, R6및 R7은 동일하거나 또는 상이한 것으로서, 각각 H,F,Cl,OH,NH2 또는 SH이고, 단 a)X가 O,S 이고 R2가 H이며, R3이 CH2OH이고, Y가 OH, NH|2이며, R5가 CH=CH2, C≡CH, CH=CHCH3, H,CH3, C2H5, CH2CH2CH3, CH(CH3)2인 경우에는 특허청구된 일반식(1A)의 화합물은 β-아노머 형태의 화합물이고, b) X가 CH2이고, R2가 H이며, R3이 CH2OH인 경우에는 특허청구된 일반식 (1A)의 화합물은 R4가(식중, R6및 R5은 동일하거나 또는 상이한 것으로서, 각각 H, CL, OH, NH2또는 SH 임)의 기인 화합물이다.
  4. α-및 β-아노머의 혼합물 또는 α-및 β-아노머 형태의 하기 일반식의 화합물 또는 그의 제약상 허용되는 염.
  6. 상기 식 중, X는 O,S,SO,SO2,CH2이고, R1은 OH, O-PO(OH)2, O-PO(OH)-O-PO-(OH)2, O-PO-(OH)-O-PO(OH)-O-PO(OH)2, 또는 (CH2)nOCH2PO(OH|2)(여기서, n은 0내지 2임)이며, R2는 H이고, R3은 CH3, CH2OH, CH2OnCH|3, CH2SH, CH2F 또는 CH2N3이거나, 또는 R3은 H이고, R2는 CH3, CH2OH, CH2OCH3, CH2SH, CH2F 또는 CH2N3이며 R4는또는이고, 여기서 Y는 OH, NH2이고 R5는 CH=CH2, C=CH, CH=CH-CH3, C=C-CH3, 티엔-2-일, 티엔-3-일, H, CH3,CH2H|5,CH2CH2CH3또는 CH(CH3)2이며, R6 및 R7은 동일하거나 또는 상이한 것으로서, 각각 H,F,Cl,OH,,NH2또는 SH이다.
  7. 제1항 또는 제2항에 있어서, X가 0인 화합물.
  8. 제1항 또는 제2항에 있어서, X가 S,SO 또는 SO2인 화합물.
  9. 제1항 또는 제2항에 있어서, X가 CH2인 화합물.
  10. 제1항 또는 제2항중 어느 한 항에 있어서, R1이 OH이고, R2가 H이고, R3이 CH2OH이거나, R3이 H이고 R2가 CH2OH인 화합물.
  11. 제1항 내지 제5항중 어느 한 항에 있어서, R1이 OH이고, R2가 H이고, R3이 CH3,CH2SH, CH2OCH3, CH2F, CH2N이거나, R3이 H이고 R2가 CH3, CH2SH, CH2OCH3, CH2F, CH2N3인 화합물.
  12. 제1항 내지 제5항중 어느 한 항에 있어서, R1이 (CH2)nCH2PO(OH)2(여기서 n이 0내지 2임)인 화합물.
  13. 제1항 내지 제8항중 어느 한 항에 있어서, X가 OH, NH2이고 R3가 H, CH3, CH=CH2, C=CH 또는 CH=CH-CH3인 화합물.
  14. 제1항 내지 제8항중 어느 한 항에 있어서, R7이 H,OH,SH 또는 NH2일때, R6이 NH2인 화합물.
  15. 제1항 내지 제8항중 어느 한 항에 있어서, R7이 OH,SH 또는 NH2일때, R6이 H,F 또는 Cl인 화합물.
  16. 제1항 내지 제8항중 어느 한 항에 있어서, R7및 R6이 OH인 화합물.
  17. 제1항 내지 제12항중 어느 한 항에 있어서, 화합물이 α-아노머 형태인 화합물.
  18. 제1항 내지 제12항중 어느 한 항에 있어서, 화합물이 β-아노머 형태인 화합물.
  19. 제1항 내지 제14항중 어느 한 항에 있어서, 치료에 유용한 일반식(1A) 및 (1B)의 화합물.
  20. 활성 성분으로서 제1항 내지 제14항중 어느 한 항 기재의 일반식(1A) 및 (1B)의 화합물 및 리포좀을 포함한 제약상 허용되는 담체로 이루어진 제약 조성물.
  21. 치료 유효량의 제1항 내지 제14항중 어느 한 항 기재의 일반식(1A) 및 (1B)의 화합물을 치료를 요하는 동물 또는 인체 숙주에 토여하는 것으로 이루어진, 동물 또는 인체 숙주의 바이러스 감염증 치료 방법.
  22. 제17항에 있어서, 인체 면역 결핍 바이러스 및 간염 B바이러스를 포함하여 복제에 역전사효소를 요하는 바이러스에 의한 감염증 치료방법.
  23. 제17항에 있어서, 헤르페스 바이러스에 의한 감염증 치료방법.
  24. 제17항에 있어서, 기생충에 의한 감염증 치료방법.
  25. 복제에 역전사효소를 요하는 바이러스에 의한 후천성 면역 결핍증 및 감염증 치료용 의약을 제조하기위한 제1항 내지 제14항 중 어느 한 항 기재의 일반식 (1A)및 (1B)의 화합물의 용도.
  26. 제21항에 있어서, HIV바이러스에 의한 감염증 치료를 위한 화합물의 용도.
  27. 제21항에 있어서, 간염 B 바이러스에 의한 감염증 치료를 위한 화합물의 용도.
  28. 제21항에 있어서, 헤르페스 바이러스에 의한 감염증 치료를 위한 화합물의 용도.
  29. 제21항에 있어서, 기생충에 의한 감염증 치료를 위한 화합물의 용도.
  30. 하기 반응식에 따라 글리코시드를 피리미딘 유도체의 N-1위치 또는 푸린 유도체의 N-9위치에 축합시키는 것으로 이루어진 하기 일반식 (1A)의 화합물의 제조방법.
  32. 상기 식중, X,R1,R2,R3및 R4는 제1항에서 정의한 바와 같고, Z는 Cl,Br, J, 아실옥시 또는 알콕시이고, R1', R2'및 R3'는 각각 상기 R1, R2및 R3에 대해 정의한 바와 같으나, 단 R1또는 R2가 OH이면 0는 보호기를 가져야 하고, R4'는 상기 R4에 대해 정의한 바와 같으나, 실릴, 아실 또는 알킬 보호기를 갖는다.
  33. 하기 반응식에 따라 글리코시드를 피리미딘 유도체의 N-1위치 또는 푸린 유도체의 N-9위치에 축합시키는 것으로 이루어진 하기 일반식(1B)의 화합물의 제조방법.
  35. 상기 식중, X,R1,R2,R3및 R4는 제1항에서 정의한 바와 같고, Z는 Cl,Br, J, 아실옥시 또는 알콕시이고, R1', R2'및 R3'는 각각 상기 R1, R2및 R3에 대해 정의한 바와 같으나, 단 R1또는 R2가 OH이면 0는 보호기를 가져야 하고, R4'는 상기 R4에 대해 정의한 바와 같으나, 실릴, 아실 또는 알킬 보호기를 갖는다.
  36. 보호된 부탄-1,4-디올-2,3- 에폭시드를 이중 결합을 갖는 탄소 원자수 3또는 4의 친핵체와 반응시킨 다음, 이중 결합을 전환시켜 페환시키는 것으로 이루어진 하기 일반식의 제조방법.
  38. 상기 식중, X,R1,R2,R3및 R4는 제1항에서 정의한 바와 같고, Z는 Cl,Br, J, 아실옥시 또는 알콕시이다.
  39. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930701006A 1990-10-02 1991-09-27 뉴클레오시드 유도체 KR930702371A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9003151-9 1990-10-02
SE9003151A SE9003151D0 (sv) 1990-10-02 1990-10-02 Nucleoside derivatives
PCT/SE1991/000653 WO1992006102A1 (en) 1990-10-02 1991-09-27 Nucleoside derivatives

Publications (1)

Publication Number Publication Date
KR930702371A true KR930702371A (ko) 1993-09-08

Family

ID=20380539

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930701006A KR930702371A (ko) 1990-10-02 1991-09-27 뉴클레오시드 유도체

Country Status (11)

Country Link
US (4) US5473063A (ko)
EP (1) EP0554274A1 (ko)
JP (1) JPH06501261A (ko)
KR (1) KR930702371A (ko)
AU (1) AU8641091A (ko)
CA (1) CA2093020A1 (ko)
HU (1) HUT63851A (ko)
IE (1) IE913374A1 (ko)
PT (1) PT99130A (ko)
SE (1) SE9003151D0 (ko)
WO (1) WO1992006102A1 (ko)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ234534A (en) * 1989-07-17 1994-12-22 Univ Birmingham Pyrimidine 4'-thionucleoside derivatives and their preparation; intermediates therefor
US5728575A (en) 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5521163A (en) * 1990-07-13 1996-05-28 University Of Birmingham Antiviral pyrimidine nucleosides and methods for using same
SE9003151D0 (sv) * 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
EP0637965B1 (en) * 1991-11-26 2002-10-16 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
TW393513B (en) * 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
GB9218810D0 (en) * 1992-09-04 1992-10-21 Univ Birmingham Antiviral pyrimidine nucleosides
WO1994021658A1 (en) * 1993-03-15 1994-09-29 Kalman Thomas I Antiviral imidazolinone nucleoside derivatives
US6200952B1 (en) * 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
FR2709754B1 (fr) * 1993-09-10 1995-12-01 Centre Nat Rech Scient Composés 2' ou 3'-déoxy- et 2', 3'-didéoxy-beta-L-pentofuranonucléosides, procédé de préparation et application thérapeutique, notamment anti-virale.
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
AU697612B2 (en) * 1994-05-31 1998-10-15 Medivir Ab Post exposure prevention of HIV
US5612319A (en) * 1994-05-31 1997-03-18 Medivir Ab Postexposure prevention of HIV infection or seroconversion
GB9413724D0 (en) * 1994-07-07 1994-08-24 Wellcome Found Therapeutic nucleosides
US5811408A (en) * 1994-07-12 1998-09-22 Yamasa Corporation 2'-deoxy-2'-(substituted or unsubstituted)methylidene-4'-thionucleosides
DE69533856T2 (de) * 1994-10-24 2005-12-08 Genencor International, Inc., Palo Alto L-pyranosyl-nukleoside
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
ES2276404T3 (es) 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
CN1201463A (zh) * 1995-11-02 1998-12-09 株式会社钟根堂 新型核苷衍生物及其制备方法
GB9600143D0 (en) 1996-01-05 1996-03-06 Wellcome Found Therapeutic compounds
US6703394B2 (en) 1996-02-16 2004-03-09 Medivir Ab Acyclic nucleoside derivatives
US5869493A (en) 1996-02-16 1999-02-09 Medivir Ab Acyclic nucleoside derivatives
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6509320B1 (en) * 1996-10-16 2003-01-21 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
ATE271063T1 (de) * 1996-10-16 2004-07-15 Icn Pharmaceuticals Purin-l-nukleoside, deren analoga und verwendungen
EP1072607A3 (en) * 1996-10-16 2001-09-12 ICN Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses therof
EP0970100B1 (en) 1997-02-13 2003-11-12 Glaxo Group Limited Benzimidazole derivatives
GB9807354D0 (en) * 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
GB9807355D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
US7019129B1 (en) 2000-05-09 2006-03-28 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
AU2003251524A1 (en) * 2002-06-17 2003-12-31 Isis Pharmaceuticals, Inc. Carbocyclic nucleoside analogs as RNA-antivirals
CA2594229A1 (en) * 2004-12-30 2006-07-06 Medivir Ab 2',3'-dideoxy-3'-c-hyroxymethylcytidine and prodrugs thereof for the treatment of drug escape mutant hiv
EP2268608A4 (en) 2008-04-01 2012-01-11 Biosearch Technologies Inc DARK NUCLEIC ACID STABILIZED FLUOROPHORE DEACTIVATOR PROBES
CN104203969B (zh) 2012-03-28 2016-08-31 富士胶片株式会社 1-(2-脱氧-2-氟-4-硫代-β-D-阿拉伯呋喃糖基)胞嘧啶的盐
KR20170001722A (ko) 2012-08-13 2017-01-04 후지필름 가부시키가이샤 1-(2-데옥시-2-플루오로-4-티오-β-D-아라비노푸라노실)시토신의 합성 중간체, 티오뉴클레오시드의 합성 중간체, 및 그들의 제조법
WO2015125781A1 (ja) 2014-02-18 2015-08-27 富士フイルム株式会社 チオラン骨格型糖化合物の製造方法およびチオラン骨格型糖化合物
JP6204223B2 (ja) 2014-02-19 2017-09-27 富士フイルム株式会社 チオピラノース化合物等の製造方法
TWI678373B (zh) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
EP4001283A1 (en) * 2015-05-12 2022-05-25 F. Hoffmann-La Roche AG Substituted aminothiazolopyrimidinedione derivatives for the treatment and prophylaxis of virus infection
SG11201901815WA (en) 2016-08-31 2019-04-29 Fujifilm Corp Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit
CA3089728C (en) 2018-01-29 2023-01-10 Fujifilm Corporation Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
CN114409655A (zh) * 2022-01-26 2022-04-29 郑州大学 3′,4′-不饱和核糖c-核苷类似物及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3116282A (en) * 1960-04-27 1963-12-31 Upjohn Co Pyrimidine nucleosides and process
FR2040177A1 (en) * 1969-01-31 1971-01-22 Robugen Gmbh 2-deoxyribosyl-uracil derivs
US3817982A (en) * 1971-12-29 1974-06-18 Syntex Inc 2{40 ,3{40 -unsaturated nucleosides and method of making
US4247544A (en) * 1979-07-02 1981-01-27 The Regents Of The University Of California C-5 Substituted uracil nucleosides
US4267171A (en) * 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
JPS57146798A (en) * 1981-03-06 1982-09-10 Yamasa Shoyu Co Ltd Hexosyl nucleoside derivative
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
EP0286825A3 (en) * 1987-03-18 1989-04-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of 3'-fluro-3' deoxythymidine for the manufacture of a medicament for the treatment of virus infections
SE8701605D0 (sv) * 1987-04-16 1987-04-16 Astra Ab Novel medicinal compounds
SE8704298D0 (sv) * 1987-11-03 1987-11-03 Astra Ab Compounds for use in therapy
SE8802173D0 (sv) * 1988-06-10 1988-06-10 Astra Ab Pyrimidine derivatives
FI95384C (fi) * 1989-04-06 1996-01-25 Squibb Bristol Myers Co Menetelmä 3'-deoksi-3'-substituoitujen metyylinukleosidien valmistamiseksi ja menetelmässä käytettäviä välituotteita
JPH03223264A (ja) * 1990-01-30 1991-10-02 Nippon Kayaku Co Ltd 新規なシクロペンタン誘導体及びその製造法
SE9003151D0 (sv) * 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
ATE273700T1 (de) * 1993-05-21 2004-09-15 Us Gov Health & Human Serv Neues verfahen zur hemmung der replication der virus - abhängigen reverse transciptase durch verwendung von dideoxydenucleotide-synthese inhibitoren
US5521161A (en) * 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide

Also Published As

Publication number Publication date
US5473063A (en) 1995-12-05
US5952500A (en) 1999-09-14
WO1992006102A1 (en) 1992-04-16
HUT63851A (en) 1993-10-28
EP0554274A1 (en) 1993-08-11
CA2093020A1 (en) 1992-04-03
IE913374A1 (en) 1992-04-08
SE9003151D0 (sv) 1990-10-02
PT99130A (pt) 1992-08-31
US6121431A (en) 2000-09-19
US5747473A (en) 1998-05-05
AU8641091A (en) 1992-04-28
JPH06501261A (ja) 1994-02-10
HU9300964D0 (en) 1993-06-28

Similar Documents

Publication Publication Date Title
KR930702371A (ko) 뉴클레오시드 유도체
KR900701815A (ko) 피리미딘 유도체
KR900701817A (ko) 뉴클레오사이드 유도체와 그의 제조방법
US4963533A (en) Therapeutic application of dideoxycytidinene
ATE115958T1 (de) Nukleoside und nukleosid-analoge, pharmazeutische zusammensetzung und verfahren für die herstellung der bestandteile.
WO2005021568B1 (en) Novel tricyclic nucleosides or nucleotides as therapeutic agents
KR890003761A (ko) 치료학적 아시클릭 뉴클레오시드
KR930006036A (ko) 퓨린 및 피리미딘의 불포화 비환식 포스포네이트 유도체
CA2070230A1 (en) Crystalline oxathiolane derivatives
KR930019213A (ko) 간염치료에 유용한 1,3-옥사티올란류
KR890003382A (ko) 항 비루스성 화합물
JPH05509307A (ja) プリンの抗ウイルス性ホスホノ―アルケン誘導体
CA2287370A1 (en) Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides
KR910000734A (ko) 네플라노신 유도체
KR910018393A (ko) 항바이러스제로서의 비대칭 2-(포스포노메톡시)프로필 구아닌
US5116822A (en) Therapeutic application of dideoxycytidinene
KR950701638A (ko) 푸린 동족체의 항비루스성 포스폰산 유도체(Antiviral phosphonic acid derivatives of purine analogues)
ES2105923A1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
PT91489B (pt) Processo para a preparacao de analogos de 3'-fluoro nucleosidos e de composicoes farmaceuticas que os contem
KR970001160B1 (ko) 2',3'-디데옥시이노신 모노히드레이트, 2',3'-디데옥시-2',3'-디데히드로티미딘 모노히드레이트 및 2',3'-디데옥시-2'-플루오로이노신 헤미히드레이트의 수용성이 높고 안정한 항비루스 결정체염
JP2926257B2 (ja) 抗ウイルス性で高い水溶性を持ち且つ安定な結晶性２′，３′‐ジデオキシイノシン・モノ水和物塩、２′，３′‐ジデオキシ‐２′，３′‐ジデヒドロチミジン・モノ水和物塩及び２′，３′‐ジデオキシ‐２′‐フルオロイノシン・ヘミ水和物塩
EP0317728A3 (en) Use of 9-(beta-d-arabinofuranosyl) adenine derivatives for the preparation of pharmaceutical compositions for the treatment of aids
KR910700256A (ko) 푸린 누클레오시드, 이들의 제조방법 및 이들 화합물을 포함하는 약제
JPS6242957A (ja) ジアミンの製法
FR2455598A1 (fr) Nouveaux derives 5- (2- ((2,3-dihydro-1,4-benzodioxanne-2-ylmethyl)- amino)-1- hydroxyethyl)-2-hydroxybenzoiques, utiles notamment comme agents bloquants des recepteurs adrenergiques a et b, et leur procede de preparation

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid